peptides for muscle growth

updated

recombinant hGH has the deepest peptide-adjacent human record on this page, and what that record documents is lean mass rather than strength. the androgen lane has different biology, evidence, and risks, so it is mapped separately rather than folded into a peptide ranking.

the muscle-and-performance peptide conversation has a real top of stack. recombinant hGH (somatropin, FDA 1985, 11 brand names) holds the deepest human trial record here, with a caveat worth reading before the rest of the page: liu 2008 (annals of internal medicine) pooled 27 randomised samples in young fit adults and found lean body mass up 2.1 kg (95% CI 1.3 to 2.9) while strength and exercise capacity did not improve. tesamorelin (Egrifta, FDA november 2010) is the only approval-grade peptide GH-axis secretagogue and the legal endocrinology-clinic alternative for body composition.

two flavors get searched below that line. gh-axis stimulators (cjc-1295, ipamorelin, sermorelin) nudge the pituitary toward larger endogenous gh pulses. direct-intervention compounds (igf-1 lr3, follistatin-344) bypass that regulation entirely. the october 2024 PCAC vote pulled ipamorelin and CJC-1295 out of routine 503A compounding. igf-1 lr3 and follistatin-344 land in F-tier because the chronic-use safety record is empty, not because the muscle signal is implausible.

androgens are not peptides and do not inherit the gh-axis record. oxandrolone, oxymetholone, and nandrolone have meaningful human data in specific medical or research populations; trenbolone, boldenone, and yk-11 have major human evidence gaps. no randomized human body-composition head-to-head of two androgen compounds was located. cross-trial outcomes are not head-to-head evidence.

recombinant hGH leads the peptide-adjacent field, tesamorelin is the approval-grade peptide alternative.

the actual hormone, then the peptide secretagogue with phase-3 trial data. these are the FDA-approved options for body composition.

  • hgh (somatropin) (tier S) · recombinant human growth hormone. genentech Protropin 1985. 11 brand names across daily and weekly cadences by 2026. · the deepest human trial record of anything on this page, and the record separates two claims that get sold as one. FDA-approved across pediatric GHD, adult GHD, Turner syndrome, Prader-Willi, HIV wasting, and more. binds the GH receptor on nearly every tissue and drives liver IGF-1, lean mass, lipolysis. in healthy adults liu 2008 (annals of internal medicine, 27 randomised samples) reports lean body mass up 2.1 kg with strength and exercise capacity unchanged, and yarasheski 1992 traced that fat-free-mass gain to tissue other than skeletal muscle. off-label use in healthy adults sits outside the approved indications and carries the cancer-risk epidemiology the approved-indication record does not cover.
  • tesamorelin (tier S) · GHRH analog. FDA-approved november 2010 as Egrifta SV for HIV-associated visceral lipodystrophy. · the only approval-grade peptide GH-axis secretagogue. falutz pivotal phase 3 (NEJM 2007, n=412) reported 15-18 percent visceral adipose reduction. pooled lipo trials cover n>800 across 26 and 52 weeks. the indication is visceral fat in HIV lipodystrophy, not muscle growth in healthy adults. tesamorelin is the cleanest legal alternative to recombinant HGH for body composition.
  • cjc-1295 + ipamorelin blend (tier A) · GHRH analog plus selective GHRP. the community-standard GH-axis stack. · us compounding pharmacies paired the two molecules in the 2010s once clinicians recognized the receptor logic. GHRH-R and GHS-R 1a fire independently; paired stimulation approximates a larger natural pulse than either alone. not an FDA-reviewed fixed-dose product. october 2024 PCAC vote pulled the components from routine 503A compounding. receptor pairing is strong. blend-specific outcome and long-term safety data remain thin.

what else gets searched, and where the data is.

the peptide entries here are unapproved or historical outside narrow indications. insulin has established diabetes evidence, not controlled healthy-person muscle-gain efficacy, and severe hypoglycemia remains an immediate risk. the adjacent androgen entries have their own formulation-specific human, foreign-label, veterinary, or preclinical records. a grade tracks evidence depth, not suitability or safety.

  • cjc-1295 (tier A) · GHRH analog with maleimidopropionic albumin handle (DAC). 6-8 day half-life. · conjuchem biotechnologies, montreal, developed CJC-1295 in the early 2000s as an adult GHD and lipodystrophy candidate. teichman 2006 phase 1 pharmacology was clean. a phase 2 lipodystrophy trial in argentina halted in 2006 after a patient died; the attending physician concluded the death was unrelated, the program never advanced and conjuchem did not commercialize. one peer-reviewed human trial, drug-development pedigree, no FDA approval. october 2024 PCAC vote pulled it from routine 503A compounding.
  • ipamorelin (tier C) · selective ghrelin-receptor agonist. raun et al. 1998 swine model: GH release at 200x effective dose with no cortisol, prolactin, FSH, LH, TSH, or ACTH movement. · lars hansen and the novo nordisk team designed NNC 26-0161 to decouple GH release from the stress-hormone axis that held back GHRP-6 and GHRP-2. raun et al. Eur J Endocrinol 1998 is the foundational paper, swine model, full GH release at 200x effective dose with the rest of the pituitary panel flat. forms the tolerable half of the cjc-1295 + ipamorelin pairing. no FDA approval. october 2024 PCAC vote pulled it from routine 503A compounding.
  • sermorelin (tier B) · GHRH(1-29). EMD Serono Geref, FDA-approved 1990 as a diagnostic and 1997 for pediatric GHD. commercially discontinued dec 2 2008. · the only GHRH analog ever FDA-approved for chronic human use. EMD Serono sold Geref from 1990 to 2008, then notified FDA of commercial-unviability discontinuation on dec 2 2008. FDA confirmed in march 2013 the withdrawal was not for safety or efficacy. compounding pharmacies inherit standing from that approval history. adult body-composition effect sizes outside the pediatric GHD indication are measured in single-digit percent.
  • hgh frag 176-191 (tier C) · c-terminal residues 176-191 of hgh. ng and wallis monash 1990s, roughly 3-fold glycerol release in obese mice. · frank ng and michael wallis at monash identified the lipolytic c-terminus aa 176-191 in the 1990s. obese-mouse work reported roughly 3-fold glycerol release. the tyrosine-stabilized cousin aod-9604 carries more human evidence than the unmodified fragment and still failed phase 2 obesity endpoints. the fat-loss story outran the published human record.
  • ghrp-2 (tier D) · first-generation gh-releasing peptide. documented cortisol and prolactin elevation. · older ghrp. ipamorelin replaced it for the reason raun 1998 made obvious: the off-target hormonal effects are measurable in the trial record. mostly historical at this point.
  • ghrp-6 (tier D) · older ghrp. defining feature is appetite stimulation via the ghrelin receptor. · still sold. the hunger signal distinguishes it from ipamorelin and is also why most modern stacks dropped it. no fda approval.
  • igf-1 lr3 (tier F) · long-acting igf-1 analog. half-life ~20-30 hours. · elevated igf-1 is one of the most-documented cancer-promotion factors in human epidemiology. lr3 produces supraphysiological elevation. the chronic-use safety profile in healthy adults outside approved indications has not been characterized. no fda approval.
  • follistatin 344 (tier F) · myostatin antagonist that broadly inhibits multiple tgf-β family proteins. · the marketing pitch is unlock myostatin, grow forever. the actual molecular biology is broad inhibition of the regulatory family that also includes tumor-suppressor signals. zero published human trials. safety dataset empty.
  • oxandrolone (anavar) (tier S) · oral 17-alpha-alkylated androgen with human PK and controlled burn outcomes; all US approvals withdrawn in 2023. · the human record is real and so are the boxed hepatic, lipid, virilization, gonadal, edema, and pediatric risks. FDA's 2023 withdrawal followed safety and effectiveness review. historical studied regimens are evidence records, not a protocol.
  • oxymetholone (anadrol) (tier S) · oral 17-alpha-alkylated anemia drug with human lean-mass outcomes and severe dose-related hepatic harm. · the NDA remains legally approved while listed US products are discontinued. randomized trials reported anabolic outcomes alongside transaminase elevations, jaundice, and adverse lipid changes. no validated human terminal half-life was located.
  • nandrolone (tier A) · 19-nor androgen with human depot PK for decanoate and phenylpropionate and a current Australian decanoate authorization. · decanoate and phenylpropionate are distinct ester and oil-depot records, not interchangeable names. human PK does not remove gonadal suppression, fertility, erythrocytosis, edema, virilization, or cardiovascular concerns.
  • trenbolone (tier F) · underground injectable androgen sought for muscle, strength, recomp, and a hard look, with animal efficacy and human observational harm signals. · Rat data support the direction of more muscle and less fat. Human interviews and surveys report physical enhancement, aggression, mood instability, and physical concerns, but no controlled human trial measured a physique result or established a safe exposure. Current US approval is limited to cattle implants.
  • yk-11 (tier F) · steroidal androgen-receptor research chemical with cell and animal findings and no controlled human trial or measured half-life. · a defined molecule and a cell-level follistatin signal do not establish human lean mass, strength, endocrine recovery, cardiovascular risk, or a safe exposure. mixed-exposure liver reports raise concern without proving single-ingredient causality.
  • insulin (tier S) · Insulin is the peptide hormone that controls blood glucose and an essential diabetes medicine. Bodybuilders use it hoping to drive nutrients into muscle, but controlled human work shows less muscle-protein breakdown, not a continuing rise in muscle-protein synthesis. · For diabetes, insulin is established and lifesaving. For muscle gain in healthy people, the reviewed PubMed and ClinicalTrials.gov searches found no controlled efficacy trial. Human mechanism studies show reduced protein breakdown, not unlimited synthesis, while severe hypoglycemia is immediate and documented.

specific-question reference.

is any peptide fda-approved for muscle growth in healthy adults?

no. tesamorelin is approved for hiv-associated visceral lipodystrophy. sermorelin was approved 1997 for pediatric ghd and discontinued commercially dec 2 2008. somatropin (hgh) is approved for documented gh deficiency and a handful of other endocrine indications. nothing on this page carries a muscle-growth indication in healthy adults. that is a gap in the regulatory record.

why are igf-1 lr3 and follistatin-344 in F-tier when the muscle signal is plausible?

tier reflects the published safety record, not the strength of the hypertrophy signal. igf-1 elevation is a documented epidemiologic cancer-promotion factor and lr3 produces supraphysiological exposure. follistatin-344 has zero published human trials and broadly inhibits the tgf-β family that includes tumor-suppressor signals. the muscle effect can be real and the safety dataset can still be empty. both are true.

what does the gh-axis trial data actually show on body composition?

modest single-digit-percent shifts in healthy adults. real but smaller than marketing language implies. tesamorelin has the deepest fda-monitored dataset (lipo trials, n>800, 15-18% visceral adipose reduction inside the hiv indication). cjc-1295 has one peer-reviewed human pk trial. ipamorelin has the raun 1998 swine selectivity paper plus a decade of clinic use. none of this is a muscle-hypertrophy phase 3.

what does the literature show on combining peptides with weight-loss compounds?

no published peptide-on-peptide combination trials. SURMOUNT and STEP ran resistance-training subgroups but did not test secretagogue stacks alongside glp-1 therapy. the evidence gap is the relevant fact.

what's in the data for older adults concerned about age-related lean-mass loss?

sermorelin has the longest fda-approval history but the approval is pediatric ghd, not adult sarcopenia. gh-axis research in older adults reports modest effects. resistance training and adequate protein remain the primary published interventions.

do peptide trials show muscle growth without resistance training?

no peptide trial does. across this page the training stimulus is the primary driver of muscle protein synthesis and the peptide effects modulate a training-driven response. one compound outside the peptide class has shown it: bhasin 1996 (NEJM, 43 men) grew triceps area 424 mm2 and quadriceps 607 mm2 on 600 mg testosterone enanthate weekly in men who did no training at all. testosterone is a 19-carbon steroid and a us schedule iii controlled substance, so it does not belong on a peptide page except as the yardstick, and it is the reason the peptide claims on this page read modest.

which androgen has the best body-composition evidence?

that depends on the population and endpoint. testosterone, oxandrolone, oxymetholone, nandrolone, methandienone, and stanozolol each have different human records, while several others are driven by veterinary, animal, or historical evidence. no randomized human body-composition head-to-head of two androgen compounds was located. cross-trial outcomes are not head-to-head evidence, and an evidence grade is not a safety ranking or recommendation.

what the safety literature reports.

what side effects are documented in the gh-axis literature?

water retention, peripheral edema, joint discomfort, transient hand paresthesias, sleep alterations. all dose-dependent. tachyphylaxis (effect-fade) is described on continuous gh-axis stimulation.

is there a cancer-risk concern with gh-axis stimulation?

elevated igf-1 is a documented cancer-promotion factor in epidemiology. gh-axis stimulation does raise igf-1. magnitudes from cjc-1295, ipamorelin, and sermorelin at clinical doses are smaller than direct igf-1 supplementation. specific cancer-incidence data in healthy adults researching these compounds outside approved indications has not been published. absence of data is not evidence of safety.

what does the long-term safety data show?

varies by compound. tesamorelin and sermorelin have the longest fda-monitored datasets inside their approved indications. cjc-1295 and ipamorelin have roughly ten years of community use but no formal long-term studies. igf-1 lr3 and follistatin-344 have effectively no characterized long-term human safety data. the mechanistic concerns are documented in the receptor biology.

what about insulin sensitivity?

gh-axis stimulation can reduce insulin sensitivity in published research. magnitudes vary across studies. the long-term healthy-adult risk record outside approved indications remains thin.

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.